Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio associated with prognosis in patients with HER2-positive early breast cancer receiving adjuvant trastuzumab?

---

Copy For Citation

Ulas A., Avci N., Kos T., Cubukcu E., Olmez O. F., Bulut N., ...More

Journal of B.U.ON. : official journal of the Balkan Union of Oncology, vol.20, pp.714-22, 2015 (SCI-Expanded)

• Publication Type: Article / Article
• Volume: 20
• Publication Date: 2015
• Journal Name: Journal of B.U.ON. : official journal of the Balkan Union of Oncology
• Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
• Page Numbers: pp.714-22
• Keywords: breast cancer, HER2 positive, lymphocytes, neutrophil, platelet, TUMOR-INFILTRATING LYMPHOCYTES, EPITHELIAL OVARIAN-CANCER, CELL LUNG-CANCER, NEUTROPHIL/LYMPHOCYTE RATIO, PRETREATMENT NEUTROPHIL, GROWTH-FACTOR, COLORECTAL-CANCER, PERIPHERAL-BLOOD, GASTRIC-CANCER, JOINT ANALYSIS
• Bursa Uludag University Affiliated: Yes

Abstract

Purpose: To investigate whether the pretreatment neutrophil lymphocyte ratio (NLR) and the platelet lymphocyte ratio (PLR) have any prognostic significance in patients with HER2-positive early breast cancer receiving adjuvant trastuzumab.